Genentech

Sangart appoints three to leadership team

Friday, February 17, 2012 12:43 PM

Sangart, a privately held biopharmaceutical company focused on oxygen-therapeutic agents, has appointed three new members to its executive team.

More... »

FDA approves Erivedge to treat skin cancer

Monday, January 30, 2012 04:02 PM

Genentech’s Erivedge (vismodegib) has been approved by the FDA to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body (metastatic).

More... »

Roche, Xenon ink $646 million pain pact

Friday, January 13, 2012 12:15 PM

Roche’s Genentech unit plans to discover compounds and diagnostics for treatment of pain by collaborating with Xenon Pharmaceuticals, based in Vancouver.

More... »

Garland joins Exelixis

Tuesday, October 25, 2011 12:52 PM

Exelixis has named J. Scott Garland as executive vice president and chief commercial officer. As the company's chief commercial officer, Gardland will oversee the commercial functions of marketing, sales and commercial operations, and collaborate closely with Exelixis' development and manufacturing teams to provide commercial perspective for cabozantinib development efforts across multiple oncology indications.

More... »

Report: U.S. medical innovation at risk without funding

Thursday, October 6, 2011 12:03 PM

U.S. venture capitalists are decreasing their investments in biopharmaceutical and medical device companies, reducing their concentration in prevalent disease areas and shifting investment away from the United States towards Europe and Asia, according to a report by the National Venture Capital Association'sMedIC Coalition.

More... »

Array signs $685 million agreement with Genentech

Tuesday, August 9, 2011 12:08 PM

Array BioPharma has signed an oncology agreement with Genentech, a member of the Roche Group, for the development of each company's small-molecule checkpoint kinase 1 (ChK-1) program. The programs include Genentech's compound GDC-0425 (RG7602), currently in phase I, and Array's compound ARRY-575, which is being prepared for an investigational new drug application to initiate a phase I trial in cancer patients.

More... »

Positive results for Curis phase II trial

Tuesday, March 29, 2011 12:46 PM

Curis, a drug development company focusing on next-generation targeted small molecule drug candidates for cancer treatment, announced a positive outcome from a pivotal phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly-owned member of the Roche Group, of GDC-0449, a first-in-class hedgehog pathway inhibitor, in patients with advanced basal cell carcinoma (BCC).

More... »

ImmunoGen touts new drug-delivering antibodies

Tuesday, March 8, 2011 10:33 AM

After forming partnerships with several major pharmaceutical companies, Waltham, Mass.-based biotech ImmunoGen wants to boost its pipeline of antibody-drug conjugates.

More... »

Sanofi’s $20 billion Genzyme buy could fuel a big pharma-biotechnology acquisition trend

Tuesday, February 22, 2011 10:06 AM

Could last Wednesday’s $20 billion Sanofi-aventis acquisition of Genzyme signal the beginning of an industry trend in which big pharmaceutical companies stop buying each other and start buying robust biotechnology firms?

More... »

Roche to cut 4,800 jobs in global restructuring plan

Thursday, December 2, 2010 11:18 AM

After absorbing Genentech, Swiss pharma giant Roche has announced its cost-cutting plans, much of which will take place in manufacturing and sales. But there will also be some significant trimming in R&D.

More... »